Peter Bach, well-known as a drug pricing researcher and pharma industry gadfly, is leaving academia for an executive role at a biotech firm that aims to develop a blood test that can detect lung cancer, the company announced Wednesday.
Bach, 56, the director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes, will become the chief medical officer of Delfi Diagnostics, a Baltimore startup that raised $100 million from a syndicate of investors in January to develop a new form of a technology, known as liquid biopsy, that can detect fragments of cancer DNA in the bloodstream.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
